APOE and glioblastoma: In vivo studies conducted on U87 glioma-bearing mice showed that RBCm-coatedNPs functionalized with DCDX peptide significantly increased the survivalrate of mice to 28.5 days, compared to RBCm-coated NPs without DCDX functionalization (23.5 days) and the control group (22days).192 Recently, Liu et al. designed a RBCm-camouflaged NP decorated with ApoE-peptide for theselective targeting of mRNA to GBM cells.